Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab
Patient Enrollment Complete For Phase III Stelara Biosimilar Study
Executive Summary
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.